The role of inflammation in sarcoma

Advances in Experimental Medicine and Biology

Volumn 816, Issue , 2014, Pages 259-313

  Radons, Jürgen ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BRIVANIB; CAPECITABINE; CEDIRANIB; CIXUTUMUMAB; DACARBAZINE; DASATINIB; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERIBULIN; EVEROLIMUS; GEMCITABINE; IFOSFAMIDE; IMATINIB; IXABEPILONE; MESNA; MOTESANIB; NILOTINIB; PACLITAXEL; PAZOPANIB; RAPAMYCIN; RETASPIMYCIN; RIDAFOROLIMUS; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVANTINIB; TRABECTEDIN; UNINDEXED DRUG; ANGIOGENIN; CELECOXIB; MICRORNA; MICRORNA 155; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN H2 SYNTHASE 2; PROSTAGLANDIN SYNTHASE; PROTEIN FOXM1; PROTEIN KINASE B; PROTEIN KINASE LYN; RAF PROTEIN; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C RECEPTOR; SONIC HEDGEHOG PROTEIN; THALIDOMIDE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ALVEOLAR SOFT PART SARCOMA; ANGIOGENESIS; ANGIOSARCOMA; APOPTOSIS; ARTICLE; BLACKFAN DIAMOND ANEMIA; BLOOM SYNDROME; BREAST METASTASIS; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CHONDROSARCOMA; CHORDOMA; CHROMOSOME TRANSLOCATION; CHRONIC INFLAMMATION; CLEAR CELL SARCOMA; DNA REPAIR; EPITHELIAL MESENCHYMAL TRANSITION; EWING SARCOMA; FAMILIAL CANCER; FAMILIAL COLON POLYPOSIS; GASTROINTESTINAL STROMAL TUMOR; GENETIC DISORDER; GENETIC PREDISPOSITION; HUMAN; INFLAMMATORY CELL; KAPOSI SARCOMA; LEIOMYOMATOSIS; LEIOMYOSARCOMA; LIPOSARCOMA; MALIGNANT FIBROUS HISTIOCYTOMA; NEUROFIBROMATOSIS; OSTEOSARCOMA; OVERALL SURVIVAL; PHYSIOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETINOBLASTOMA; ROTHMUND THOMSON SYNDROME; SARCOMA; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; SURVIVAL TIME; WERNER SYNDROME; CANCER THERAPY; CARCINOGENESIS; CARCINOSARCOMA; CELL INVASION; CELL TRANSFORMATION; DISEASE ASSOCIATION; DRUG RESPONSE; GENE PRODUCT; INFLAMMATION; METASTASIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SARCOMA CELL; TREATMENT OUTCOME; TUMOR VASCULARIZATION;

EID: 84959190662     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-348-837-8_11     Document Type: Article

References (393)

1. Abo A, Pick E, Hall A et al (1991) Activation of the NADPH oxidase involves the small GTPbinding protein p21rac1. Nature 353:668-670
2. Abraham J, Nelon LD, Kubicek CB et al (2011) Pr eclinical testing of erlotinib in a transgenic alveolar rhabdomyosarcoma mouse model. Sarcoma 2011:130484. doi:10.1155/2011/130484
3. Aggarwal BB, Gehlot P (2009) Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol 9:351-369
4. Agulnik M (2012) New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma. Cancer 118:1486-1497
5. Agulnik M, Yarber JL, Okuno SH et al (2013) An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol 24:257-263
6. Akimoto R, Pawankar R, Yagi T et al (2000) Acquired and congenital cholesteatoma: determination of tumor necrosis factor-alpha, intercellular adhesion molecule-1, interleukin-1-alpha and lymphocyte functional antigen-1 in the inflammatory process. ORL J Otorhinolaryngol Relat Spec 62:257-265
7. Alleyne CH Jr, He J, Yang J et al (1999) Analysis of cyclin dependent kinase inhibitors in malignant astrocytomas. Int J Oncol 14:1111-1116
8. Ancrile B, Lim KH, Counter CM (2007) Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 21:1714-1719
9. Atai NA Bansal M Lo C et al 2011 Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma Immunology 132: 39-48
10. Baamonde A, Curto-Reyes V, Juarez L et al (2007) Antihyperalg esic effects induced by the IL-1 receptor antagonist anakinra and increased IL-1beta levels in inflamed and osteosarcomabearing mice. Life Sci 81:673-682
11. Bache M, Kappler M, Wichmann H et al (2010) Elevated tumor and serum levels of the hypoxiaassociated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. BMC Cancer 10:132. doi:10.1186/1471-2407-10-132
12. Bai Y, Li J, Fang B et al (2012) Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res 72:2501-2511
13. Barbie DA, Tamayo P, Boehm JS et al (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462:108-112
14. Bassuk AG, Leiden JM (1997) The role of Ets transcription factors in the development and function of the mammalian immune system. Adv Immunol 64:65-104
15. Bay JO, Ray-Coquard I, Fayette J et al (2006) Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer 119:706-711
16. Benassi MS, Gamberi G, Magagnoli G et al (2001) Metalloproteinase expression and prognosis in soft tissue sarcomas. Ann Oncol 12:75-80
17. Bernstein-Molho R, Kollender Y, Issakov J et al (2012) Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas. Cancer Chemother Pharmacol 70:855-860
18. Birchmeier C, Birchmeier W, Gherardi E et al (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925
19. Bond GL, Hu W, Bond EE et al (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591-602
20. Bruynzeel AM, Niessen HW, Bronzwaer JG et al (2007) The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study. Br J Cancer 97:10 84-1089
21. Burningham Z, Hashibe M, Spector L et al (2012) The epidemiology of sarcoma. Clin Sarcoma Res 2:14. doi:10.1186/2045-3329-2-14
22. Butrynski JE, D'Adamo DR, Hornick JL et al (2010) Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 363:1727-1733
23. Butz H, Liko I, Czirjak S et al (2010) Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas. J Clin Endocrinol Metab 95:E181-E191
24. Calvert GT, Randall RL, Jones KB et al (2012) At-risk populations for osteosarcoma: the syndromes and beyond. Sarcoma 2012:152382. doi:10.1155/2012/152382
25. Carmody Soni EE, Miller BJ, Scarborough MT et al (2011) Cyclooxygenase-2 expression is not associated with clinical outcome in synovial sarcoma. Oncol Rep 26:1513-1517
26. Carrasco DR, Fenton T, Sukhdeo K et al (2006) The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. Cancer C ell 9:379-390
27. Castilla MA, Moreno-Bueno G, Romero-Perez L et al (2011) Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol 223:72-80
28. Castro-Gamero AM, Borges KS, da Silva Silveira V et al (2012) Inhibition of nuclear factor-kappaB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells. Anticancer Drugs 23:638-650
29. Cen L, Hsieh FC, Lin HJ et al (2007) PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound. Br J Cancer 97:785-791
30. Chandran UR, Ma C, Dhir R et al (2007) Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 7:64. doi:10.1186/1471-2407-7-64
31. Chang PL, Cao M, Hicks P (2003) Osteopontin induction is required for tumor promoter-induced transformation of preneoplastic mouse cells. Carcinogenesis 24:1749-1758
32. Chaturvedi MM, Sung B, Yadav VR et al (2011) NF-κB addiction and its role in cancer: 'one size does not fit all'. Oncogene 30:1615-1630
33. Chawla SP, Staddon AP, Baker LH et al (2012) Phase I I study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 30:78-84
34. Chen TC, Hinton DR, Apuzzo ML et al (1993) Differential effects of tumor necrosis factor-alpha on proliferation, cell surface antigen expression, and cytokine interactions in malignant gliomas. Neurosurgery 32:85-94
35. Chen Y, Takita J, Mizuguchi M et al (2007) Mutation and expression analyses of the MET and CDKN2A genes in rhabdomyosarcoma with emphasis on MET overexpression. Genes Chromosom Cancer 46:348-358
36. Chen YJ, Wei YY, Chen HT et al (2009) Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. J Cell Physiol 2 21:98-108
37. Chien Y, Kim S, Bumeister R et al (2006) RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 127:157-170
38. Choi JK, Choi BH, Ha Y et al (2007) Signal transduction pathways of GM-CSF in neural cell lines. Neurosci Lett 420:217-222
39. Christensen L, Joo J, Lee S et al (2013) FOXM1 Is an oncogenic mediator in Ewing sarcoma. PLoS ONE 8:e54556
40. Chugh R, Griffith KA, Brockstein B et al (2012) Phase I study of doxorubicin (D) plus anti-insulin-like growth factor 1 receptor (IGF-1R) a ntibody cixutumumab (IMC-A12) in advanced soft tissue sarcoma (STS). J Clin Oncol 30:10028
41. Colotta F, Allavena P, Sica A et al (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073-1081
42. Constam DB, Philipp J, Malipiero UV et al (1992) Differential expression of transforming growth factor-beta 1,-beta 2, and-beta 3 by glioblastoma cells, ast rocytes, and microglia. J Immunol 148:1404-1410
43. Cordon-Cardo C, Latres E, Drobnjak M et al (1994) Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54:794-799
44. Cortes J, Montero AJ, Gluck S (2012) Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. Cancer Treat Rev 38:143-151
45. Cortes J, O'Shaughnessy J, Loesch D et al (2011) Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914-923
46. Crago AM, Singe r S (2011) Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Curr Opin Oncol 23:373-378
47. Curran CS, Evans MD, Bertics PJ (2011) GM-CSF production by glioblastoma cel ls has a functional role in eosinophil survival, activation, and growth factor production for enhanced tumor cell proliferation. J Immunol 187:1254-1263
48. D'Adamo DR, Anderson SE, Albritton K et al (2005) Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 23:7135-7142
49. Das P, Kotilinga m D, Korchin B et al (2007) High prevalence of p53 exon 4 mutations in soft tissue sarcoma. Cancer 109:2323-2333
50. Datta SR, Brunet A, Greenberg ME (1999) Cellular survival: a play in three Akts. Genes Dev 13:2905-2927
51. Davis AM, O'Sullivan B, Turcotte R et al (2005) Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sa rcoma. Radiother Oncol 75:48-53
52. Debiec-Rychter M Dumez H Judson I et al 2004 Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointe stinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group Eur J Cancer 40:689-695
53. Demetri GD, Chawla SP, von Mehren M et al (2009a ) Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 27:4188-4196
54. Demetri GD, Heinrich MC, Fletcher JA et al (2009b ) Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer R es 15:5902-5909
55. Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480
56. Deng X, Ewton DZ, Friedman E (2009) Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by reducing levels of reactive oxygen species. Cancer Res 69:3317-3324
57. Dickson MA, Okuno SH , Keohan ML et al (2013) Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Ann Oncol 24:252-257
58. Ding Y, Boguslawski EA, Berghuis BD et al (2008) Mitogen-acti vated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma. Mol Cancer Ther 7:648-658
59. Dong P, Kaneuchi M, Watari H et al (2011) MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer 10:99. doi:10.1186/1476-4598-10-99
60. Douglas JL, Gustin JK, Moses AV et al (2010) Kaposi sarcoma pathogenesis: a triad of viral infection, oncogenesis and chronic inflammation. Transl Biomed 1:pii 172
61. Downward J (2009) Cancer: a tumour gen e's fatal flaws. Nature 462:44-45
62. Edris B, Wi llingham SB, Weiskopf K et al (2013) Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth. Proc Natl Acad Sci USA 110:3501-3506
63. Efeyan A, Sabatini DM (2010) mT OR and cancer: many loops in one pathway. Curr Opin Cell Biol 22:169-176
64. Ellis SR, Gleizes PE (2011) Diamond Blackfan anemia: ribosomal proteins going rogue. Semin Hematol 48:89-96
65. Enders GH (2010) Gauchos and ochos: a Wee1-Cdk tango regulating mitotic entry. Cell Div 5:12. doi:10.1186/1747-1028-5-12
66. Endo M, Yamamoto H, Setsu N et al (2013) Prognostic Significance of AKT/mTO R and MAPK Pathways and Antitumor Effect of mTOR Inhibitor in NF1-Related and Sporadic Malignant Peripheral Nerve Sheath Tumors. Clin Cancer Res 19:450-461
67. Engin F, Bertin T, Ma O et al (2009) Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum Mol Genet 18:1464-1470
68. Fasanaro P, Capogrossi MC, Martelli F (2010) Regulation of the endothelial cell cycle by the ubiquitin-proteasome system. Cardiovasc Res 85:272-280
69. Fata F, O'Reilly E, Ilson D et al (1999) Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 86:2034-2037
70. Feldman AL, Pak H, Yang JC et al (2001) Serum endostatin levels are elevated in patients with soft tissue sarcoma. Cancer 91:1525-1529
71. Felgenhauer JL, Nieder ML, Krailo MD et al (2013) A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893. Pediatr Bl ood Cancer 60:409-414
72. Fernandez M, Pino AM, Figueroa P et al (2010) The increased expression of receptor activator of nuclear-kappaB ligand (RANKL) of multiple myeloma bone marrow stromal cells is inhibited by th e bisphosphonate ibandronate. J Cell Biochem 111:130-137
73. Fernandez-Medarde A Santos E 2011 Ras in cancer and developmental diseases Genes Cancer 2
74. Ferrari A, Sultan I, Huang TT et al (2011) Soft tissue sarcoma across the age spectrum: a populationbased study from the surveillance epidemiology and end results database. Pediatr Blood Cancer 57:943-949
75. Fletcher O, Easton D, Anderson K et al (2004) Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst 96:357-363
76. Fontana A, Hengartner H, de Tribolet N et al (1984) Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol 132:1837-1844
77. Forbes SA, Bind al N, Bamford S et al (2011) COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39:D945-D950
78. Foreman KE, Wrone-Smith T, Boise LH et al (1996) Kaposi's sarcoma tumor cells preferentially express Bcl-xL. Am J Pathol 149:795-803
79. Frei K, Piani D, Malipiero UV et al (1992) Granulocyte-macrophage colony-stimulating factor (GM-CSF) production by glioblas toma cells. Despite the presence of inducing signals GM-CSF is not expressed in vivo. J Immunol 148:3140-3146
80. Friedman E (2011) The role of mirk kinase in sarcomas. Sarcoma 2011:260757. doi:10.1155/2011/260757
81. Friedrichs N, Kuchler J, Endl E et al (2008) Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma. J Pathol 216:428-439
82. Fu W, Ma L, Chu B et al (2011) The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells. Mol Cancer Ther 10:1018-1027
83. Fukuda T, Yamaguchi T, Yamaki T et al (2001) Ovarian fibrosarcoma producing multiple cytokines. Pathol Int 51:739-743
84. Fuller CK, Charlson JA, Dankle SK et al (2010) Dramatic improvement of inoperable angiosarcoma with combination paclitaxel an d bevacizumab chemotherapy. J Am Acad Dermatol 63:e83-e84
85. Garcia K, Stumpff J, Duncan T et al (2009) Tyrosines in the kinesin-5 head domain are necessary for phosphorylation by Wee1 and for mitotic spin dle integrity. Curr Biol 19:1670-1676
86. Garcia-Carbonero R, Supko JG, Manola J et al (2004) Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues re fractory to chemotherapy. J Clin Oncol 22:1480-1490
87. Gardner K, Judson I, Leahy M et al (2009) Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma . J Clin Oncol 27:10523. http://meeting.ascopubs.org/cgi/content/abstract/27/15S/ 10523?sid=cbb7 71a3-21c0-4634-955b-60ff724c1f3a
88. Gendy AS, Lipskar A, Glick RD et al (2011) Selective inhibition of cyclo oxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma. J Pediatr Surg 46:108-114
89. Gennatas C, Michalaki V, Kairi PV et al (2012) Successful treat ment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor. World J Surg Oncol 10:181
90. George S, Blay JY, Casali PG et al (2009) Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45:19 59-1968
91. Gisselsson D, Palsson E, Hoglund M et al (2002) Differentially amplified chromosome 12 sequences in low-and high-grade osteosarcoma. Genes Chromosom Cancer 33:133-140
92. Giuffrida A Y, Burgueno JE, Koniaris LG et al (2009) Chondrosarcoma in the United States (1973-2003): an analysis of 2,890 cases from the SEER database. J Bone Joint Surg Am 91:1063-1072
93. Grignani G, Palmer ini E, Dileo P et al (2012) A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 23:508-516
94. Grimer R, Athanasou N, Gerrand C et al (2010a) UK guidelines for the management of bone sarcomas. Sarcoma 2010:317462. doi:10.1155/2010/317462
95. Grimer R, Judson I, Peake D et al (2010b) Guidelines for the management of soft tissue sarcomas. Sarcoma 2010:506182. doi:10.1155/2010/506182
96. Gronchi A, Blay JY, Trent JC (2010) The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor. Cancer 116:1847-1858
97. Gronchi A, Bui BN, Bonvalot S et al (2012) Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol 23:771-776
98. Guan H, Zhou Z, Gallick GE et al (2008) Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Mol Cancer Ther 7:1807-1816
99. Guertin DA, Sabatini DM (2005) An expanding role for mTOR in cancer. Trends Mol Med 11:353-361
100. Gupta AA, Yao X, Verma S et al (2013) Systematic chemotherapy for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a systematic review. Clin Oncol (R Coll Radiol) 25:346-355
101. Hacker H, Karin M (2006) Regulation and function of IKK and IKK-related kinases. Sci STKE 2006:re13
102. Hafeez BB, Ahmed S, Wang N et al (2006) Green tea polyphenols-induced apoptosis in human osteosarco ma SAOS-2 cells involves a caspase-dependent mechanism with downregulation of nuclear factor-kappaB. Toxicol Appl Pharmacol 216:11-19
103. Hahnel A, Wichmann H, Greither T et al (2012) Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients. BMC Cancer 12:131. doi:10.1186/1471-2407-12-131
104. Hansen MF, Koufos A, Gallie BL et al (1985) Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci USA 82:6216-6220
105. Harbitz F (1924) Chronische und akute Entzündungen als Ursache für Sarkom. Acta Pathol Microbiol Scand 1:438-447
106. Harbour JW (2001) Molecular basis of low-penetrance retinoblastoma. Arch Ophthalmol 119:1699-1704
107. Hashimoto O, Shinkawa M, To rimura T et al (2006) Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line. BMC Cancer 6:292. doi:10.1186/1471-2407-6-292
108. Hassan SE, Beka rev M, Kim MY et al (2012) Cell surface receptor expression patterns in osteosarcoma. Cancer 118:740-749
109. Haupt Y, Harris AW, Adams JM (1992) Retroviral infection accelerates T lymphomagenesis in E mu-N-ras transgenic mice by activating c-myc or N-myc. Oncogene 7:981-986
110. He S, Li P, Chen CH et al (2012) Effective oncolytic vaccinia therapy for human sarcomas. J Surg Res 175:e53-e60
111. Heinrich MC, Corless CL, Demetri GD et al (2003a ) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349
112. Heinrich MC, Corless CL, Duensing A et al (2003b ) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708-710
113. Heinrich MC, Maki RG, Corless CL et al (2008) Primary an d secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26:5352-5359
114. Heinsohn S, Evermann U, Zur SU et al (2007) Determination of the prognostic value of loss of heterozygosity at the retinoblastoma gene in osteosarcoma. Int J Oncol 30:1205-1214
115. Hensley ML, Blessing JA, Degeest K et al (2008a ) Fixe d-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol 109:323-328
116. Hensley ML, Blessing JA, Mannel R et al (2008b ) Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 109:329-334
117. Hernando E Charytonowicz E Dudas ME et al 2007 The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas Nat Med 13: 748-753
118. Hettmer S, Liu J, Miller CM et al (2011) Sarcomas induced in discrete subsets of prospectively isolated skeletal muscle cells. Proc Natl Acad Sci USA 108:20002-20007
119. Hillegass JM, Shukla A, Lathrop SA et al (2010a) Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Ann NY Acad Sci 1203:7-14
120. Hillegass JM, Shukla A, MacPherson MB et al (2010b) Utilization of gene profiling and proteomics to determine mineral pathogenicity in a human mesothelial cell line (LP9/TERT-1). J Toxicol Environ Health A 73:423-436
121. Hirakaw a N, Naka T, Yamamoto I et al (1996) Overexpression of bcl-2 protein in synovial sarcoma: a comparative study of other soft tissue spindle cell sarcomas and an additional analysis by fluorescence in situ hybridization. Hum Pathol 27:1060-1065
122. Hirama M, Takahashi F, Takahashi K et al (2003) Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett 198:107-117
123. Hiromura K, Pippin JW, Fero ML et al (1999) Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27(Kip1). J Clin Invest 103:597-604
124. Hisaoka M, Matsuyama A, Nagao Y et al (2011) Identification of altered MicroRNA expression patterns in synovial sarcoma. Genes Chromosom Cancer 50:137-145
125. Ho AL, Vasudeva SD, Lae M et al (2012) PDGF receptor alpha is an alternati ve mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma. Cancer Res 72:4515-4525
126. Hogendoorn PC, Collin F, Daugaard S et al (2004) Changing concepts in the pathological basis of soft tissue and bone sarcoma treatment. Eur J Cancer 40:1644-1654
127. Hoki Y, Hiraku Y, Ma N et al (2007a ) iNOS-dependent DNA damage in patients with malignant fibrous histiocytoma in relation to prognosis. Cancer Sci 98:163-168
128. Hoki Y, Murata M, Hiraku Y et al (2007b ) 8-Nitroguanine as a potential biomarker for progression of malignant fibrous histiocytoma, a model of inflammation-related cancer. Oncol Rep 18:1165-1169
129. Hö nicke AS, Ender SA, Radons J (2012) Combined administration of EGCG and IL-1 receptor antagonist efficiently downregulates IL-1-induced tumorigenic factors in U-2 OS human osteosarcoma cells. Int J Oncol 41:753-758
130. Honma M, Higuchi O, Shirakata M et al (2006) Dok-3 sequesters Grb2 and inhibits the Ras-Erk pathway downstream of protein-tyrosine kinases. Genes Cells 11:143-151
131. Houghton PJ, Morton CL, Kolb EA et al (2008) Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 50:799-805
132. Huang HY, Kang HY, Li CF et al (2006) Skp2 overexpression is highly representative of intrinsic biological aggressiveness and independently associated with poor prognosis in primary localized myxofibrosarc omas. Clin Cancer Res 12:487-498
133. Huang X, Choi JK, Park SR et al (2007) GM-CSF inhibits apoptosis of neural cells via regulating the expression of apoptosis-related proteins. Neurosci Res 58:50-57
134. Hussain SP, Harris CC (2007) Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 121:2373-2380
135. Ishii E, Ohga S, Aoki T et al (1991) Prognosis of children with virus-associated hemophagocytic syndrome and malignant histiocytosis: correlation with levels of serum interleukin-1 and tumor necrosis factor. Acta Haematol 85:93-99
136. Italiano A, Delcambre C, Hostein I et al (2010) Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol 21:1135-1137
137. Ivanov SV, Ivanova AV, Goparaju CM et al (2009) Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. Biochem Biophys Res Commun 382:514-518
138. Iwasaki H Nabeshima K Nishio J et al 2009 Pathology of soft-tissue tumors: daily diagnosis, molecular cytogenetics and experimental approachi Pathol Int 59: 501-521
139. Jackson AL, Loeb LA (2001) The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat Res 477:7-21
140. Jacobs H, Bast A, Peters GJ et al (2011) The semisynthetic flavonoid monoHER sensitises human soft tissue sarcoma cells to doxorubicin-induced apoptosis via inhibition of nuc lear factor-kappaB. Br J Cancer 104:437-440
141. Jin K, Park S, Ewton DZ et al (2007) The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer. Cancer Res 67:7247-7255
142. Juergens H, Daw NC, Geoerger B et al (2011) Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 29:4534-4540
143. Kalinichenko VV, Major ML, Wang X et al (2004) Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev 18:830-850
144. Kansara M, Thomas DM (2007) Molecular pathogenesis of osteosarcoma. DNA Cell Biol 26:1-18
145. Kasper B, Ouali M, van Glabbeke M et al (2013) Progno stic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: a study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 62931. Eur J Cancer 49:449-456
146. Keller SA, Hernandez-Hopkins D, Vider J et al (2006) NF-kappaB is essential for the progression of KSHV-and EBV-infected lymphomas in vivo. Blood 107:3295-3302
147. Kirla RM, Haapasalo HK, Kalimo H et al (2003) Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas. Cancer 97:644-648
148. Kirsch DG, Dinulescu DM, Mille r JB et al (2007) A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med 13:992-997
149. Kishimoto K, Liu S, Tsuji T et al (2005) Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene 24:445-456
150. Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823
151. Kobayashi H, Yagyu T, Kondo T et al (2005) Suppression of urokinase receptor expression by thalidomide is associated with inhibition of nuclear factor kappaB activation and subsequently suppressed ovarian cancer dissemination. Cancer Res 65:10464-10471
152. Koch M, Nielsen GP, Yoon SS (2008) Malignant tumors of blood vessels: angiosarcomas, hemangioendotheliomas, and hemangioperictyomas. J Surg Oncol 97:321-329
153. Koga K, Nabeshima K, Aoki M et al (2007) Emmprin in epithelioid sarcoma: expression in tumor cell membrane and stimulation of MMP-2 production in tumor-associated fibroblasts. Int J Cancer 120:761-768
154. Koga K, Nabeshima K, Nishimura N et al (2005) Microvessel density and HIF-1alpha expression correlate with malignant potential in fibrohistiocytic tumors. Eur J Dermatol 15:465-469
155. Kohashi K, Oda Y, Yamamoto H et al (2008) Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype. J Cance r Res Clin Oncol 134:1097-1103
156. Koshiji M, To KK, Hammer S et al (2005) HIF-1α induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell 17:793-803
157. Kraljevic Pavelic S, Sedic M, Bosnjak H et al (2011) Metastasis: new perspectives on an old problem. Mol Cancer 10:22. doi:10.1186/1476-4598-10-22
158. Kuhnen C, Herter P, Muller O et a l (2000) Beta-catenin in soft tissue sarcomas: expression is related to proliferative activity in high-grade sarcomas. Mod Pathol 13:1005-1013
159. Kummar S, Strassberger A, Monks A et al (2011) An eval uation of cediranib as new agent for alveolar soft part sarcoma (ASPS). J Clin Oncol 29:10001. http://meeting.ascopubs.org/cgi/content/abstract/29/15-suppl/10001? sid=629fd0d8-f8f1-4905-816e-134f8d1ad715
160. Kundu JK, S urh YJ (2008) Inflammation: gearing the journey to cancer. Mutat Res 659:15-30
161. Kundu JK, Surh YJ (2012) Emerging avenues linking inflammation and cancer. Free Radic Biol Med 52:2013-2037
162. Kushlinskii NE, Babkina IV, Solov'ev YN et al (2000) Vascular endothelium growth fac tor and angiogenin in the serum of patients with osteosarcoma and Ewing's tumor. Bull Exp Biol Med 130:691-693
163. Ladanyi M, Cha C, Lewis R et al (1993) MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 53:16-18
164. Ladetto M, Vallet S, Trojan A et al (2005) Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood 105:4784-4791
165. Lahat G, Lazar A, Lev D (2008) Sarcoma epidemiology and etiology: potential environmental and genetic factors. Surg Clin North Am 88:451-481
166. Lahat G, Zhang P, Zhu QS et al (2011) The expression of c-Met pathway components in unclassified pleomorphic sarcoma/malignant fibrous histiocytoma (UPS/MFH): a tissue microarray study. Histopathology 59:556-561
167. Lambert LA, Qiao N, Hunt KK et al (2008) Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res 68:7966-7974
168. Langenau DM, Keefe MD, Storer NY et al (2007) Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev 21:1382-1395
169. Laoukili J, Kooistra MR, Bras A et al (2005) FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 7:126-136
170. Launonen V, Vierimaa O, Kiuru M et al (2001) Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci USA 98:3387-3392
171. Lazar AJ, Das P, Tuvin D et al (2007) Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clin Cancer Res 13:7314-7321
172. Le Cesne A, Ray-Coquard I, Bui BN et al (2010) Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 11:942-949
173. Lea ch FS, Tokino T, Meltzer P et al (1993) p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53:2231-2234
174. Lee HJ, Kim SA, Lee HJ et al (2010) Paeonol oxime inhibits bFGF-induced angiogenesis and reduces VEGF levels in fibrosarcoma cells. PLoS ONE 5:e12358
175. Lee J, Ku T, Yu H et al (2012) Blockade of VEGF-A suppresses tumor growth via inhibition of autocrine signaling through FAK and AKT. Cancer Lett 318:221-225
176. Lee J, Lee J, Yu H et al (2011) Differential dependency of human cancer cells on vascular endothelial growth factor-mediated autocrine growth and survival. Cancer Lett 309:145-150
177. Lee JC, Simon PL, Young PR (1989) Constitutive and PMA-induced interleukin-1 production by the human astrocytoma cell line T24. Cell Immunol 118:298-311
178. Lee SH, McCormick F (2005) Downregulation of Skp2 and p27/Kip1 synergistically induces apoptosis in T98G glioblastoma cells. J Mol Med (Berl) 83:296-307
179. Lehtonen HJ, Kiuru M, Ylisaukko-oja SK et al (2006) Increased risk of cancer in patients with fumarate hydratase germline mutation. J Med Genet 43:523-526
180. Leidner RS, Aboulafia DM (2005) Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS 19:635-644
181. Lemay S Davidson D Latour S et al 2000 Dok-3, a novel adapter molecule involved in the negative regulation of immunoreceptor signaling Mol Cell Biol 20: 2743-2754
182. Lewis AM, Varghese S, Xu H et al (2006) Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 4:48. doi:10.1186/1479-5876- 4-48
183. Li A, Dubey S, Varney ML et al (2003) IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 170:3369-3376
184. Li FP, Fraumeni JF Jr (1969) Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71:747-752
185. Li G, Kawashima H, Ogose A et al (2011) Efficient virotherapy for osteosarcoma by telomerasespecific oncolytic adenovirus. J Cancer Res Clin Oncol 137:1037-1051
186. Li Y, Zhang J, Ma D et al (2012) Curcumin inhibits proliferation and invasion of osteosarcoma cells through inactivation of Notch-1 signaling. FEBS J 279:2247-2259
187. Lin WW, Karin M (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117:1175-1183
188. Lipton JM, Federman N, Khabbaze Y et al (2001) Osteogenic sarcoma associated with Diamond-Blackfan anemia: a report from the Diamond-Blackfan Anemia Registry. J Pediatr Hematol Oncol 23:39-44
189. Liu B, Qu L, Yang Z et al (2012a) Cyclooxygenase-2 inhibitors induce anoikis in osteosarcoma via PI3K/Akt pathway. Med Hypotheses 79:98-100
190. Liu J, Hettmer S, Milsom MD et al (2012b) Induction of histiocytic sarcoma in mouse skeletal muscle. PLoS ONE 7:e44044
191. Liu M, Dai B, Kang SH et al (2006) FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res 66:3593-3602
192. Liu SJ, Zhang DQ, Sui XM et al (2008) The inhibition of in vivo tumorigenesis of osteosarcoma (OS)-732 cells by antisense human osteopontin RNA. Cell Mol Biol Lett 13:11-19
193. Liu X, Newton RC, Scherle PA (2010) Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med 16:37-45
194. Longhi A, Benassi MS, Molendini L et al (2001) Osteosarcoma in blood relatives. Oncol Rep 8:131-136
195. Lu Y, Yu Q, Liu JH et al (2003) Src family protein-tyrosine kinases alter the function of PTEN to regu late phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem 278:40057-40066
196. Luke JJ, D'Adamo DR, Dickson MA et al (2012) The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. Clin Cancer Res 18:2638-2647
197. Lund SA, Giachelli CM, Scatena M (2009) The role of osteopontin in inflammatory processes. J Cell Commun Signal 3:311-322
198. Lyles SE, Milner RJ, Kow K et al (2012) In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines. Vet Comp Oncol 10:223-235
199. Ma Q, Cavallin LE, Yan B et al (2009) Antitumorigenesis of antioxidants in a transgenic Rac1 model of Kaposi's sarcoma. Proc Natl Acad Sci USA 106:8683-8688
200. Maeyama H, Hidaka E, Ota H et al (2001) Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 120:210-215
201. Maki RG, D'Adamo DR, Keohan ML et al (2009) Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 27:3133-3140
202. Maki RG Wathen JK Patel SR et al 2007 Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 (corrected J Clin Oncol 25 2755-2763
203. Malempati S, Weigel B, Ingle AM et al (2012) Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 30:256-262
204. Malkin D, Li FP, Strong LC et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238
205. Mallery SR, Pei P, Landwehr DJ et al (2004) Implications for oxidative and nitrative stress in the pathogenesis of AIDS-related Kaposi's sarcoma. Carcinogenesis 25:597-603
206. Mantovani A, Allavena P, Sica A et al (2008) Cancer-related inflammation. Nature 454:436-444
207. Marampon F, Bossi G, Ciccarelli C et al (2009) MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma. Mol Cancer Ther 8:543-551
208. Marees T, Moll AC, Imhof SM et al (2008) Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst 100:1771-1779
209. Martin Liberal J, Lagares-Tena L, Sainz-Jaspeado M et al (2012) Targeted therapies in sarcomas: challenging the challenge. Sarcoma 2012:626094. doi:10.1155/2012/626094
210. Martinelli S, McDowell HP, Vigne SD et al (2009) RAS signaling dysregulation in human embryonal Rhabdomyosarcoma. Genes Chromosom Cancer 48:975-982
211. Mashima R, Honda K, Yang Y et al (2010) Mice lacking Dok-1, Dok-2, and Dok-3 succumb to aggressive histiocytic sarcoma. Lab Invest 90:1357-1364
212. May WA, Gishizky ML, Lessnick SL et al (1993) Ewing sarcoma 11; 22 translocation pr oduces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci USA 90:5752-5756
213. McMeekin DS, Sill MW, Darcy KM et al (2012) A phase II tri al of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study. Gynecol Oncol 127:356-361
214. Melhem MF, Meisler AI, Saito R et al (1993) Cytokines in inflammatory malignant fibrous histiocytoma presenting with leukemoid reaction. Blood 82:2038-2044
215. Menczer J, Schreiber L, Sukmanov O et al (2010) COX-2 expression in uterine carcinosarcoma. Acta Obstet Gynecol Scand 89:120-125
216. Mercer SE, Ewton DZ, Shah S et al (2006) Mirk/Dyrk1b mediates cell survival in rhabdomyosarcomas. Cancer Res 66:5143-5150
217. Mesri EA, Cesarman E, Boshoff C (2010) Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 10:707-719
218. Meta-analysis (2010) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 28:1247-1253
219. Minobe S, Todo Y, Suzuki Y et al (2011) Mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy for uterine leiomyosarcoma: a report of two cases. J Obstet Gynaecol Res 37:645-649
220. Mirabello L, Troisi RJ, Sava ge SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115:1531-1543
221. Mita MM, Poplin E, Britten CD et al (201 3) Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma. Ann Oncol 24:1104-1111
222. Mollapou r M, Tsutsumi S, Neckers L (2010) Hsp90 phosphorylation, Wee1 and the cell cycle. Cell Cycle 9:2310-2316
223. Momand J, Zambetti GP, Olson DC et al (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245
224. Mori K, Berreur M, Blanchard F et al (2007) Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modu lates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. Oncol Rep 18:1365-1371
225. Moroianu J, Riordan JF (1994) Nuclear translocation of angiogenic proteins in endothelial cells: an essential step in angiogenesis. Biochemistry 33:12535-12539
226. Muftuoglu M, Oshima J, von Kobbe C et al (2008) The clinical characteristics of Werner syndrome: molecular and biochemical diagnosis. Hum Genet 124:369-377
227. Multhoff G, Molls M, Radons J (2012) Chronic inflammation in cancer development. Front Immunol 2:98. doi:10.3389/fimmu.2011.00098
228. Multhoff G, Radons J (2012) Radiation, inflammation, and immune responses in cancer. Front Oncol 2:58. doi:10.3389/fonc.2012.00058
229. Murai A, Abou AS, Kodama A et al (2012a) Immunohistochemical analysis of the Akt/mTOR/4E-BP1 signalling pathway in canine haemangiomas and haemangiosarcomas. J Comp Pat hol 147:430-440
230. Murai A, Asa SA, Kodama A et al (2012b) Constitutive phosphorylation of the mTORC2/Akt/4EBP1 pathway in newly derived canine hemangiosarcoma cell lines. BMC Vet Res 8:128. d oi:10.1186/1746-6148-8-128
231. Naganuma H, Sasaki A, Satoh E et al (1996) Modulation of transforming growth factor-beta secretio n from malignant glioma cells by interleukin-1 beta. Neurol Med Chir (Tokyo) 36:145-150
232. Nagata Y, Lan KH, Zhou X et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117-127
233. Naing A, LoRusso P, Fu S et al (2012) Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor te msirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res 18:2625-2631
234. Nakagawa SA, Lopes A, de Lopes CA et al (2010) Nitric oxide synthases, cyclooxygenase-2, nitrotyrosine, and angiogenesis in chondrosarcoma and their relation to prognosis. J Bone Joint Surg Am 92:1738-1746
235. Nakayama Y, Kato N, Nakajima Y et al (2004) Effect of TNF-alpha on human osteosarcoma cell line Saos2-T NF-alpha regulation of bone sialoprotein gene expression in Saos2 osteoblastlike cells. Cell Biol Int 28:653-660
236. Navid F, Letterio JJ, Yeung CL et al (2000) Autocrine transforming growth factor-beta gro wth pathway in murine osteosarcoma cell lines associated with inability to affect phosphorylation of retinoblastoma protein. Sarcoma 4:93-102
237. Ng CH, Xu S, Lam KP (2007) Dok-3 plays a nonredundant role in negative regulation of B-cell activation. Blood 110:259-266
238. Ng PK, Tsui SK, Lau CP et al (2010) CCAAT/enhancer binding protein beta is up-regulated in giant cell tumor of bone and regulates RANKL expression. J Cell Biochem 110:438-446
239. Noguchi SI, Ueki T, Kawauchi S et al (1997) Establishment and characterization of a new synovial sarcoma cell line, SN-SY-1: special reference to bcl-2 protein and SYT-SSX1 hy brid transcripts. Int J Cancer 72:995-1002
240. Nö r JE, Christensen J, Mooney DJ et al (1999) Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell surv ival and induction of Bcl-2 expression. Am J Pathol 154:375-384
241. O'Hara AJ, Wang L, Dezube BJ et al (2009) Tumor suppressor microRNAs are underrepresented in primary effusion lymphoma and Kaposi sarcoma. Blood 113:5938-5941
242. O'Sullivan B, Davis AM, Turcotte R et al (2002) Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 359:2235-2241
243. Obana K, Yang HW, Piao HY et al (2003) Aberrations of p16INK4A, p14ARF and p15INK4B genes in pediatric solid tumors. Int J Oncol 23:1151-1157
244. Ohshima H, Sawa T, Akaike T (2006) 8-nitroguanine, a product of nitrative DNA damage caused by reactive nitrogen species: formation, occurrence, and implications in inflammation and carcinogenesis. Antioxid Redox Signal 8:1033-1045
245. Oldenborg PA Gresham HD Lindberg FP 2001 CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis J Exp Med 193:855-862
246. Olmos D, Pos tel-Vinay S, Molife LR et al (2010) Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 11:129-135
247. Park HJ, Carr JR, Wang Z et al (2009) FoxM1, a critical regulator of oxidative stress during oncogenesis. EMBO J 28:2908-2918
248. Park MS, Patel SR, Ludwig JA et al (2011) Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer 117:4939-4947
249. Pass HI, Lott D, Lon ardo F et al (2005) Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353:1564-1573
250. Paudel N, Sadagopan S, Chakraborty S et al (2012) Kaposi's sarcoma-associat ed herpesvirus latency-associated nuclear antigen interacts with multifunctional angiogenin to utilize its antiapoptotic functions. J Virol 86:5974-5991
251. Peng CL, Guo W, Ji T et al (2009) Sorafenib induc es growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway. Cancer Biol Ther 8:1729-1736
252. Pervaiz N, Colterjohn N, Farrokhyar F et al (2008) A sys tematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 113:573-581
253. Petricoin EFI, Espina V, Araujo RP et al (2007) Phosphopro tein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 67:3431-3440
254. Petrioli R, Coratti A, Correale P et al (2002) Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma. Am J Clin Oncol 25:468-473
255. Pilarsky C, Wenzig M, Specht T et al (2004) Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia 6:744-750
256. Piva R, Cavalla P, Bortolotto S et al (1997) p27/kip1 expression in human astrocytic gliomas. Neurosci Lett 234:127-130
257. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915-928
258. Pollard P, Wortham N, Barclay E et al (2005a ) Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome. J Pathol 205:41-49
259. Pollard PJ, Briere JJ, Alam NA et al (2005b ) Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14:2231-2239
260. Postel-Vinay S, Veron AS, Tirode F et al (2012) Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nat Genet 44:323-327
261. Prakash O, Swamy OR, Peng X et al (2005) Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis. Blood 105:3987-3994
262. Prieur A, Tirode F, Cohen P et al (2004) EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 24:7275-7283
263. Priller M, Poschl J, Abrao L et al (2011) Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients. Clin Cancer Res 17:6791-6801
264. Purohit S, Bhise R, Appachu S et al (2011) Systemic therapy in soft tissue sarcomas: past, present and future. Indian J Surg Oncol 2:327-331
265. Quek R, Wang Q, Morgan JA et al (2011) Combination mTOR and IGF-1R inhibitio n: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 17:871-879
266. Quesada J Amato R 2012The molecular biology of soft-tissue sarcomas and current trends in therapy Sarcoma 2012:849456 doi:10.1155/2012/849456
267. Radons J, Bosserhoff AK, Grassel S et al (2006a ) p38MAPK mediates IL-1-induced down-regulation of aggrecan gene expression in human chondrocytes. Int J Mol Med 17:661-668
268. Radons J, Falk W, Schubert TE (2006 b ) Interleukin-10 does not affect IL-1-induced interleukin-6 and metalloproteinase production in human chondrosarcoma cells, SW1353. Int J Mol Med 17:377-383
269. Rao PK, Missiaglia E, Shields L et al (2010) Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB J 24:3427-3437
270. Raut CP, Nawrocki S, Lashinger LM et al (2004) Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xe nografts. Cancer Biol Ther 3:1217-1224
271. Ray-Coquard I, Italiano A, Bompas E et al (2012) Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). Oncologist 17:260-266
272. Reed S, Li H, Li C et al (2011) Celecoxib inhibits STAT3 phosphorylation and suppresses cell migration and colony forming ability in rhabdomyosarcoma cells. Biochem Biophys Res Commun 407:450-455
273. Restrepo CS, Ocazionez D (2011) Kaposi's sarcoma: imaging overview. Semin Ultrasound CT MR 32:456-469
274. Reuter S, Gupta SC, Chaturvedi MM et al (2010) Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 49:1603-1616
275. Riggi N, Suva ML, De Vito C et al (2010) EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev 24:916-932
276. Roma J, Masia A, Reventos J et al (2011) Notch pathway inhibition significantly reduces rhabdomyosarcoma invasiveness and mobility in vitro. Clin Cancer Res 17:505-513
277. Rose-John S, Schooltink H (2007) Cytokines are a therapeutic target for the prevention of inflammation-induced cancers. Recent Results Cancer Res 174:57-66
278. Rosen A, Thimon S, Ternant D et al (2010) Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face. Br J Dermatol 163:225-227
279. Rosen N, Bolen JB, Schwartz AM et al (1986) Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. J Biol Chem 261:13754-13759
280. Ross KA, Smyth NA, Murawski CD et al (2013) The biology of Ewing sarcoma. ISRN Oncol 2013:759725. doi:10.1155/2013/759725
281. Rubin AI, Stiller MJ (2002) A listing of skin conditions exhibiting the Koebner and pseudo-Koebner phenomena with eliciting stimuli. J Cutan Med Surg 6:29-34
282. Rubin BP, Heinrich MC, Corless CL (2007) Gastrointestinal stromal tumour. Lancet 369:1731-1741
283. Rubin BP, Nishijo K, Chen HI et al (2011) Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell 19:177-191
284. R utkowski P, Kaminska J, Kowalska M et al (2003) Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol 84:151-159
285. Sa dagopan S, Sharma-Walia N, Veettil MV et al (2009) Kaposi's sarcoma-associated herpesvirus upregulates angiogenin during infection of human dermal microvascular endothelial cells, which induces 45S rRNA synthesis, antiapoptosis, cell proliferation, migration, and angiogenesis. J Virol 83:3342-3364
286. Sadagopan S, Veettil MV, Chakraborty S et al (2012) Angiogenin functionally interacts with p53 and regulates p53-mediated apoptosis and cell survival. Oncogene 31:4835-4847
287. Sandau KB, Faus HG, Brune B (2000) Induction of hypoxia-inducible-factor 1 by nitric oxide is mediated via the PI 3K pathway. Biochem Biophys Res Commun 278:263-267
288. Sarcoma Meta-analysis Collaboration (1997) Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 350:1647-1654
289. Sasaki K, Hitora T, Nakamura O et al (2011) The role of MAPK pathway in bone and soft tissue tumors. Anticancer Res 31:549-553
290. Sasaki M, Ikeda H, Itatsu K et al (2008) The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab Invest 88:873-882
291. Sastry KV, Sharma SC, Mann SB et al (1999) Aural cholesteatoma: role of tumor necrosis factoralpha in bone destruction. Am J Otol 20:158-161
292. Savage SA, Mirabello L (2011) Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma 2011:548151. doi:10.1155/2011/548151
293. Scheidler S, Fredericks WJ, Rauscher FJ III et al (1996) The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture. Proc Natl Acad Sci USA 93:9805-9809
294. Schiffer D, Cavalla P, Fiano V et al (2002) Inverse relationship between p27/ Kip.1 and the F-box protein Skp2 in human astrocytic gliomas by immunohistochemistry and Western blot. Neurosci Lett 328:125-128
295. Schoffski P, Adkins D, Blay J et al (2011a) Phase II trial of anti-IGF-IR ant ibody cixutumumab in patients with advanced or metastatic soft-tissue sarcoma and Ewing family of tumors. J Clin Oncol 29:10004. http://meeting. ascopubs.org/cgi/content/abstract/29/15-suppl/10004? sid=a6464a16-77fd-4537- baa7-c98ad3b1 e0bc
296. Schoffski P, Ray-Coquard IL, Cioffi A et al (2011b) Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol 12:1045-10 52
297. Schuetze SM, Zhao L, Chugh R et al (2012) Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma. Eur J Cancer 48:1347-1353
298. Schwartz GK, Maki RG, Undevia SD et al (2011) Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): biomarker and subset results of a phase II randomized discontinuation trial. J Clin Oncol 29:1000
299. Schwartz GK, Tap WD, Qin LX et al (2012) A phase II multicenter study of the IGF-1 receptor antibody cixutumumab (A12) and the mTOR inhibitor temsirolimus (TEM) in patients (pts) with refractory IGF-1R positive (+) and negative (- ) bone and soft tissue sarcomas (STS). J Clin Oncol 30:10003. http://meeting.ascopubs.org/cgi/content/abstract/30/15-suppl/10003 ?sid=80ce8716-8c84-4aa3-a0db-6843813c51d1
300. Scotlandi K, Avnet S, Benini S et a l (2002) Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int J Cancer 101:11-16
301. Serrano M, Lee H, C hin L et al (1996) Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:27-37
302. Shah MH, Porcu P, Mallery SR et al (2002) AIDS-associated malignancies. Cancer Chemother Biol Response Modif 20:633-664
303. Sharma-Walia N, Paul AG, Bottero V et al (2010) Kaposi's sarcoma associated herpes virus (KSHV) induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion. PLoS Pathog 6:e1000777
304. Sharma-Walia N, Raghu H, Sadagopan S et al (2006) Cyclooxygenase 2 induced by Kaposi's sarcoma-associated herpesvirus early during in vitro infection of target cells plays a role in the maintenance of latent viral gene express ion. J Virol 80:6534-6552
305. Shekar SC, Wu H, Fu Z et al (2005) Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit. J Biol Chem 280: 27850-27855
306. Shen Z, Hoffman JD, Hao F et al (2012) More than just skin deep: faciocutaneous clues to genetic syndromes with malignancies. Oncologist 17:930-936
307. Shimada S Ishizawa T Ishizawa K et al 2006 The value of MDM2 and CDK4 amplification levels using real-time polymerase chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers Hum Pathol 37: 1123-1129
308. Shor AC, Keschman EA, Lee FY et al (2007) Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 67:2800-2808
309. Shukla A, MacPherson MB, Hillegass J et al (2009) Alterations in gene expression in human mesothelial cells correlate with mineral pathogenicity. Am J Respir Cell Mol Biol 41:114-123
310. Silva I, Branco JC (2011) Rank/Rankl/opg: literature review. Acta Reumatol Port 36:209-218
311. Simonart T, Van Vooren JP (2002) Interleukin-1 beta increases the BCL-2/BAX ratio in Kaposi's sarcoma cells. Cytokine 19:259-266
312. Singh M, Pandey A, Karikari CA et al (2010) Cell cycle inhibition and apoptosis induced by curcumin in Ewing sarcoma cell line SK-NEP-1. Med Oncol 27:1096-1101
313. Sinkovics JG (2007 a ) Adult human sarcomas. I. Basic science. Expert Rev Anticancer Ther 7:31-56
314. Sinkovics JG (2007 b ) Adult human sarcomas. II. Medical oncology. Expert Rev Anticancer Ther 7:183-210
315. Sinkovics JG (2012) Molecular biology of oncogenic inflammatory processes. I. Non-oncogenic and oncogenic pathogens, intrinsic inf lammatory reactions without pathogens, and micro-RNA/DNA interactions (Review). Int J Oncol 40:305-349
316. Sivakumar R, Sharma-Walia N, Raghu H et al (2008) Kaposi's sarcoma-associated herpesvirus induces sustai ned levels of vascular endothelial growth factors A and C early during in vitro infection of human microvascular dermal endothelial cells: biological implications. J Virol 82:1759-1776
317. Skubitz KM, Haddad PA (2005) Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 104:361-366
318. Sleijfer S, Ouali M, van Glabbeke M et al (2010) Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group ( EORTC-STBSG). Eur J Cancer 46:72-83
319. Sleijfer S, Ray-Coquard I, Papai Z et al (2009) Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 27:3126-3132
320. Smida J, Baumhoer D, Rosemann M et al (2010) Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma. Clin Cancer Res 16:4256-4267
321. Sparmann A, Bar-Sagi D (2004) Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6:447-458
322. Spurrell EL, Fisher C, Thomas JM et al (2005) Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the R oyal Marsden Hospital. Ann Oncol 16:437-444
323. Stacchiotti S, Dagrada GP, Morosi C et al (2012a) Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib. Clin Sarcoma Res 2:22. doi:10.1186/2045-3329-2-22
324. Stacchiotti S, Negri T, Libertini M et al (2012b) Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol 23:3171-3179
325. Stettner MR, Wang W, Nabors LB et al (2005) Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. Cancer Res 65:5535-5543
326. Stiller CA, Trama A, Serraino D et al (2013) Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer 49:684-695
327. Stojadinovic A, Leung DH, Hoos A et al (2002) Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg 235:424-434
328. Sturgis EM Potter BO 2003Sarcomas of the head and neck region Curr Opin Oncol 15:239-252
329. Subramanian S, Lui WO, Lee CH et al (2008) MicroRNA expression signature of human sarcomas. Oncogene 27:2015-2026
330. Suhasini AN, Brosh RM Jr (2013) DNA helicases associated with genetic instability, cancer, and aging. Adv Exp Med Biol 767:123-144
331. Sun SG, Lau YS, Itonaga I e t al (2006) Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation. J Pathol 209:114-120
332. Ta HT, Dass CR, Choong PF et al (2009) Osteosarcoma treatment: state of the art. Cancer Metastasis Rev 28:247-263
333. Takahashi F, Akutagawa S, Fukumoto H et al (2002) Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int J Cancer 98:707-712
334. Takamori H, Oades ZG, Hoch OC et al (2000) Autocrine growth effect of IL-8 and GROα on a human pancreatic cancer cell line, Capan-1. Pancreas 21:52-56
335. Takebe N, Harris PJ, Warren RQ et al (2011) Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8:97-106
336. Tamburini BA, Phang TL, Fosmire SP et al (2010) Gen e expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma. BMC Cancer 10:619. doi:10.1186/1471-2407-10-619
337. Tanaka M, Setoguchi T, Hirotsu M et al (2009) Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br J Cancer 100:1957-1965
338. Tap WD, Demetri G, Barnette P et al (2012) Phase II study of ganitumab, a ful ly human antitype-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol 30:1849-1856
339. Tat SK, Pelletier JP, Velasco CR et al (2009) New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target? Keio J Med 58:29-40
340. Taulli R, Bersani F, Foglizzo V et al (2009) The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest 119:2366-2378
341. Taylor R, Knowles HJ, Athanasou NA (2011) Ewing sarcoma cells express RANKL and support osteoclastogenesis. J Pathol 225:195-202
342. Thomas ES, Gomez HL, Li RK et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210-5217
343. Tili E, Michaille JJ, Wernicke D et al (2011) Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proc Natl Acad Sci USA 108:4908-4913
344. Tolcher AW, Sarantopoulos J, Patnaik A et al (2009) Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 27:5800-5807
345. Tomlinson IP, Alam NA, Rowan AJ et al (2002) Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30:406-410
346. Toretsky JA, Gorlick R (2010) IGF-1R targeted treatment of sarcoma. Lancet Oncol 11:105-106
347. Toro JR, Travis LB, Wu HJ et al (2006) Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveil lance, epidemiology and end results program, 1978-2001: an analysis of 26,758 cases. Int J Cancer 119:2922-2930
348. Tsumura H, Yoshida T, Saito H et al (2006) Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice. Oncogene 25:7673-7679
349. Urakawa H, Nishida Y, Naruse T et al (2009) Cyclooxygenase-2 overexpression predicts poor survival in patients with hi gh-grade extremity osteosarcoma: a pilot study. Clin Orthop Relat Res 467:2932-2938
350. Valero V, Vrdoljak E, Xu B et al (2012) Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecita bine in patients with anthracycline-and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials. Clin Breast Cancer 12:240-246
351. van den Boom J, Wolte r M, Kuick R et al (2003) Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol 163:1033-1043
352. van der Graaf WT, Blay JY, Chawla SP et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879-1886
353. van Oosterom AT, Mouridsen HT, Nielsen OS et al (2002) Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first-and second-line chemotherapy in ad vanced soft tissue sarcoma patients. Eur J Cancer 38:2397-2406
354. Vemulapalli S, Mita A, Alvarado Y et al (2011) The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas. Target Oncol 6:29-39
355. Verma S, Younus J, Stys-Norman D et al (2008) Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. Cancer Treat Rev 34:339-347
356. Verweij J, Baker LH (2010) Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations. Eur J Cancer 46:863-868
357. Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127-1134
358. Virchow R (1859) Die Cellularpathologie in ihrer Begründung auf physiologische und pathologische Gewebelehre. August Hirschwald, Berlin
359. Virchow R (1863) Die krankhaften Geschwülste. August Hirschwald, Berlin
360. von Mehren M, Rankin C, Goldblum JR et al (2012) Phase 2 Southwest Oncology Groupdirected intergroup trial (S0505) of sor afenib in advanced soft tissue sarcomas. Cancer 118:770-776
361. Voronov E, Carmi Y, Apte RN (2007) Role of IL-1-mediated inflammation in tumor angiogenesis. Adv Exp Med Biol 601:265-270
362. W agner AJ, Goldberg JM, Dubois SG et al (2012) Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription
363. Wan X, Helman LJ (2007) The biology behind mTOR inhibition in sarcoma. Oncologist 12:1007-1018
364. Wang IC, Chen YJ, Hughes D et al (2005a ) Forkhead box M1 regulates th e transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol 25:10875-10894
365. Wang J, Ouyang W, Li J et al (2005b ) Loss of tu mor suppressor p53 decreases PTEN expression and enhances signaling pathways leading to activation of activator protein 1 and nuclear factor kappaB induced by UV radiation. Cancer Res 65:6601-6611
366. Wang LL, Gannavarapu A , Kozinetz CA et al (2003) Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst 95:669-674
367. Wang Z, Park HJ, Carr JR et a l (2011) FoxM1 in tumorigenicity of the neuroblastoma cells and renewal of the neural progenitors. Cancer Res 71:4292-4302
368. Wardelmann E, Losen I, Hans V et al (2003) Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 106:887-895
369. Wilker E, Bol D, Kiguchi K et al (1999) Enhanc ement of susceptibility to diverse skin tumor promoters by activation of the insulin-like growth factor-1 receptor in the epidermis of transgenic mice. Mol Carcinog 25:122-131
370. Wong FL, Boice JD Jr, Abramson DH et al (1997) Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 278:1262-1267
371. Wong TF, Takeda T, Li B et al (2011) Curcumin disrupts uterine leiomyosarcoma cells through AKT-mTOR pathway inhibition. Gynecol Oncol 122:141-148
372. Wu SP Huang TC Lin CC et al 2012) Pardaxin, a fish antimicrobial peptide, exhibits antitumor activity toward murine fibrosarcoma in vitro and in vivo. Mar Drugs 10: 1852-1872
373. Xia JJ, Pei LB, Zhuang JP et al (2010) Celecoxib inhibits beta-catenin-dependent survival of the human osteosarcoma MG-63 cell line. J Int Med Res 38:1294-1304
374. Xia SJ, Barr FG (2005) Chromosome translocations in sarcomas and the emergence of oncogenic transcription factors. Eur J Cancer 41:2513-2527
375. Xie X, Ghadimi MP, Young ED et al (2011) Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma. Clin Cancer Res 17:5901-5912
376. Yaich S, Charfeddine K, Zaghdane S et al (2012) Sirolimus for the treatment of Kaposi sarcoma after renal transplantation: a series of 10 cases. Transpl Proc 44:2824-2826
377. Yan D, Dong XE, Chen X et al (2009) MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem 284:29596-29604
378. Yang C, Ji D, Weinstein EJ et al (2010a) The kinase Mirk is a potential therapeutic target in osteosarcoma. Carcinogenesis 31:552-558
379. Yang MH, Hsu DS, Wang HW et al (2010b) Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol 12:982-992
380. Yang Q, Guan KL (2007) Expanding mTOR signaling. Cell Res 17:666-681
381. Yao C, Lin Y, Chua MS et al (2007) Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. Int J Cancer 121:1949-1957
382. Yarber JL, Agulnik M (2011) Targeted therapies in bone sarcomas: current approach and future directions. Expert Opin Investig Drugs 20:973-979
383. Ye F, La ttif AA, Xie J et al (2012) Nutlin-3 induces apoptosis, disrupts viral latency and inhibits expression of angiopoietin-2 in Kaposi sarcoma tumor cells. Cell Cycle 11:1393-1399
384. Ye L, Zhang HY, Wang H et al (2005) Effects of transforming growth factor beta 1 on the growth of rhabdomyosarcoma cell line RD. Chin Med J 118:678-686 (Engl
385. Yetiser S, Satar B, Aydin N (2002) Expression of epidermal growth factor, tumor necrosis factoralpha, and interleukin-1alpha in chronic otitis media with or without cholesteatoma. Otol Neurotol 23:647-652
386. Yoo J, Robinson RA, Lee JY (1999) H-ras and K-ras gene mutations in primary human soft tissue sarcoma: concomitant mutations of the ras genes. Mod Pathol 12:775-780
387. Yovine A, Riofrio M, Blay JY et al (2004) Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 22:890-899
388. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9:798-809
389. Yu Y, Khan J, Khanna C et al (2004) Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Me d 10:175-181
390. Zha J, Lackner MR (2010) Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res 16:2512-2517
391. Zhang P, Bill K, Liu J et al (2012) MiR-155 is a liposarcoma oncogene that targets casein kinase-1alpha and enhances beta-catenin signaling. Cancer Res 72:1751-1762
392. Zhang Y, Zhang N, Dai B et al (2008) FoxM1B transcriptiona lly regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. Cancer Res 68:8733-8742
393. Zibat A Missiaglia E Rosenberger A et al 2010 Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma Oncogene 29: 6323-6330